Clinical trial · Observational
Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer
Prospective Study of Tirapazamine Targeting in Cervical Cancer
NCT00493376CI-TRIAL-00006173terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study was a companion study to another one. The other study closed early so this one did as well.
Summary
Brief summary (as posted)
The purpose of this study is as follows: * to determine whether tirapazamine damages cervical tumour DNA immediately after its administration * to determine the blood flow and oxygen level of cervical tumour before and after treatment with tirapazamine
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervix Cancer | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha | Procedure | — | UNRESOLVED |
| Biopsy: Measurement of histone gamma H2AX phosphorylation | Procedure | — | UNRESOLVED |
| Cervical tissue biopsy analysis: Comet assay | Procedure | — | UNRESOLVED |
| Measurement of vascular perfusion: contrast enhanced MRI | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed clinically visible invasive carcinoma of the cervix, either squamous cell, adenocarcinoma or a variant of these * Patients must be enrolled in NCIC CXC.1 (phase 3 study assessing the addition of tirapazamine) and randomized to the tirapazamine arm * No known bleeding disorder * Willing to undergo a clinical exam to obtain tissue biopsy for hypoxia marker analysis and DNA damage assessments Exclusion Criteria: * Inability to give informed consent * Criteria below for contrast MRI only : 1. Chronic renal disease currently on dialysis 2. Renal insufficiency defined as a Glomerular Filtration Rate (GFR) ≤15cc/min , serum Cr \>130, or a BUN\>7 measured 3. Current pacemaker, tens neuro-stimulator, implanted drug infusion devices, any metal implants, foreign metals objects in eyes, aneurysm clips
References
Publications (0)
Data not yet available
No reference posted for this study.